Bacterial Membrane Coating Potentiates Lipid Nanoparticles for mRNA Delivery
Source abstract
Abstract
Bacterial outer membrane vesicles (OMVs) possess intrinsic immunostimulatory properties by carrying native antigens and pathogen-associated molecular patterns (PAMPs). Lipid nanoparticles (LNPs) have become the leading platform for messenger ribonucleic acid (mRNA) delivery, underpinning the clinical success of mRNA vaccines. Here, we developed a hybrid nanoparticle formulation, OMV-coated LNPs (OMV-LNPs), that combines the high delivery efficiency of LNPs with the immunogenicity of the OMVs to enhance gene delivery. Using Escherichia coli -derived OMVs and dengue virus (DENV) E80 protein as a model antigen, we generated OMV-LNPs encapsulating DENV mRNA (OMV-LNP mRNA ). These nanoparticles demonstrated improved uptake by lymph-node-resident immune cells and enhanced cytosolic mRNA delivery, resulting in robust dendritic cell maturation and proinflammatory cytokine production in vitro . In AG129 mice, the OMV-LNP mRNA elicited significantly higher titers of DENV-neutralizing antibodies compared to conventional LNPs. Collectively, these results establish OMV-LNPs as a versatile and potent platform for effective mRNA vaccine delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Bacterial Infections and Vaccines · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K. C. Chien and Peter Farrell Collaboratory
University of California─San Diego
Funding
Defense Threat Reduction Agency
References (31)
Show source-provided references
1. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
2. 10.1002/adma.20170675910.1002/adma.201706759 ↗
3. 10.1021/nl504798g10.1021/nl504798g ↗
4. 10.1002/anbr.20220013010.1002/anbr.202200130 ↗
5. 10.1002/pmic.20080027310.1002/pmic.200800273 ↗
6. 10.3390/pharmaceutics1302013110.3390/pharmaceutics13020131 ↗
7. 10.1101/gad.129990510.1101/gad.1299905 ↗
8. 10.1038/nri383710.1038/nri3837 ↗
9. 10.1038/s41467-021-22308-810.1038/s41467-021-22308-8 ↗
10. 10.1016/j.biomaterials.2023.12206510.1016/j.biomaterials.2023.122065 ↗
11. 10.1038/s41573-021-00283-510.1038/s41573-021-00283-5 ↗
12. 10.1038/nrd427810.1038/nrd4278 ↗
13. 10.1038/nrd.2016.28010.1038/nrd.2016.280 ↗
14. 10.1038/s41563-024-02116-310.1038/s41563-024-02116-3 ↗
15. 10.1038/s41563-025-02240-810.1038/s41563-025-02240-8 ↗
16. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
17. 10.1016/S0140-6736(23)02444-310.1016/S0140-6736(23)02444-3 ↗
18. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
19. 10.1038/s41573-024-01042-y10.1038/s41573-024-01042-y ↗
20. 10.1016/j.lanepe.2021.10020810.1016/j.lanepe.2021.100208 ↗
21. 10.1172/JCI16795510.1172/JCI167955 ↗
22. 10.1002/adma.20210998410.1002/adma.202109984 ↗
23. 10.1002/advs.20230242310.1002/advs.202302423 ↗
24. 10.1038/s41590-022-01168-410.1038/s41590-022-01168-4 ↗
25. 10.1038/s41541-023-00760-510.1038/s41541-023-00760-5 ↗
26. 10.1080/15476286.2024.233312310.1080/15476286.2024.2333123 ↗
27. 10.3389/fimmu.2025.152096810.3389/fimmu.2025.1520968 ↗
28. 10.1016/j.vaccine.2017.09.06310.1016/j.vaccine.2017.09.063 ↗
29. 10.1016/j.omtm.2020.07.01310.1016/j.omtm.2020.07.013 ↗
30. 10.1038/s41551-025-01343-610.1038/s41551-025-01343-6 ↗
31. 10.1128/JVI.02482-2010.1128/JVI.02482-20 ↗